Novo Nordisk A/S (NYSE:NVO) Shares Sold by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. trimmed its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 74.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 209,866 shares of the company's stock after selling 608,019 shares during the period. Alyeska Investment Group L.P.'s holdings in Novo Nordisk A/S were worth $18,053,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. GQG Partners LLC grew its stake in Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after purchasing an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $404,910,000. Loomis Sayles & Co. L P grew its position in shares of Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after buying an additional 2,947,771 shares during the last quarter. Clearbridge Investments LLC raised its stake in shares of Novo Nordisk A/S by 59.8% during the 4th quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock worth $368,451,000 after acquiring an additional 1,602,549 shares in the last quarter. Finally, Sustainable Growth Advisers LP lifted its position in Novo Nordisk A/S by 23.6% during the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock valued at $459,416,000 after acquiring an additional 1,021,498 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Price Performance

NVO stock traded up $1.20 during midday trading on Wednesday, reaching $67.49. The stock had a trading volume of 14,140,917 shares, compared to its average volume of 6,295,360. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company's fifty day simple moving average is $70.60 and its 200 day simple moving average is $87.08. The company has a market cap of $302.88 billion, a price-to-earnings ratio of 20.51, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.